Daiichi Sankyo and Charleston Laboratories, Inc., through its subsidiary LOCL Pharma, Inc., have entered into a strategic collaboration for the development and U.S. commercialization of Charleston’s hydrocodone combination products, including CL-108, being studied for the treatment of moderate to severe pain and the reduction of Opioid-Induced Nausea and Vomiting (OINV).    CL-108 combines 12.5 mg of immediate-release promethazine with 7.5 mg of hydrocodone and 325 mg of acetaminophen. Cha...